|
楼主 |
发表于 2008-12-16 09:49:57
|
显示全部楼层
40-5-第五节 小 结
肺动脉高压是风湿病的一个常见的肺部并发症,可见于几乎所有的风湿病,主要见于系统性硬化、混合性结缔组织病和系统性红斑狼疮。合并风湿病的肺动脉高压与原发性肺动脉高压在病理、临床和治疗方面有很多相似之处。肺动脉高压的预后较差,前列环素及其类似物,以及其他新治疗的出现,使肺动脉高压的预后得到了明显改善。
5 w9 v: V1 ^1 S (徐凯峰) u3 [+ n" Z- w' T( ?% H) m& W
参考文献2 b* |, ~! ?4 q2 {
2 K2 [* J+ `- |& `" W 高天明,肺动脉高压和原发性肺动脉高压.见:蔡柏蔷主编,21世纪医师丛书:呼吸内科分册.北京:中国协和医科大学出版社,2000.477一489. 0 v8 Q E, [3 }
' z- n" U' ]" q2 \
Alpert MA, Pressly TA, Mukerji V, et al. Short- and long-term hemodynamic effects of captopril in patients with pulmonaryhypertension and selected connective tissue disease. Chest, 1992.102:1407一1412 ) o) x; n& E4 E; s
0 K; Z+ \8 Z6 v6 [( h; A Badesch DB, Tapson VF, McGoon MD, et al. Continuousintravenous epoprostenol for pulmonary hypertension due to thescleroderma spectrum of disease. A randomized, controlled trial.Ann Intern. Med,2000.132:425一434
j4 n+ p- f& q U" B" ?" U
7 @8 o4 N% }" B6 o Barst RJ, Rubin LJ,Long WA, et al. A comparison of con-tinuous intravenous epoprostenol (prostacyclin) with conventionaltherapy for primary pulmonary hypertension. The Primary Pul-monary Hypertension Study Group. N Engl J Med, 1996. 334:296一302 , ~' h3 N1 L6 p; B9 ?, l9 z
3 c& f, {7 J; x5 x: b" I
Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma.Chest,1996.110:1515一1519
, H/ j8 H; r- W3 `: l" B1 { W) z+ p1 [2 u6 |8 B+ S
British Cardiac Society Guidelines and Medical Practice Com-mittee. Recommendations on the management of pulmonary hy-pertension in clinical practice. Heart, 2001.86(Suppl)I:I1一13
. [0 ^% [7 w3 C3 E S k
6 C3 g$ p- B r# S% j4 X0 x Burdt MA, Hoffman RW, Deutscher SL, et al. Long-termoutcome in mixed connective tissue disease: longitudinal clinicaland serologic findings. Arthritis Rheum, 1999. 42: 899一909 2 C% r; j/ f+ v C/ r% k$ O
- |* O$ [8 f* q- E
Channick RN, Simonneau G, Sitbon O, et al. Effects of thedual endothelin-receptor antagonist bosentan in patients with pul-monary hypertension: a randomised placebo-controlled study.Lancet,2001.358:1119一1123
5 t: f+ U( e. Q" n- i) n
* u' x( p6 P6 A6 E Dawson JK, Goodson NG, Graham DR, et al. Raised pulmonary artery pressures measured with Doppler echocardiographyin rheumatoid arthritis patients. Rheumatology(Oxford),2000.39:1320一1325 ; C* {- c7 c$ {7 d8 X; D
( }! }" b4 m3 J2 P! t' Z2 @& }1 o
Espinosa G, Cervera R, Font J, et al. The lung in the an-tiphospholipid syndrome. Ann Rheum Dis,2002.61 :195一198
! N' e7 Q% F; m% s7 a* ~& B/ j) }' E# h8 P2 C. p. C
Galie N, Manes A, Branzi A. Medical therapy of pulmonaryhypertension. The prostacyclins. Clin Chest Med, 2001.22:529一37 2 W) b" j. }5 v3 E( v! N& |
3 d6 ? t/ ]7 i5 t Gurubhagavatula 1, Palevsky HI. Pulmonary hypertension insystemic autoimmune disease. Rheum. Dis Clin North Am, 1997.23:365一394
! P) a z2 n( d" k0 U7 b6 n7 y
" N$ d* i6 h4 q) I: @9 T Hinderliter AL, Willis PW, Barst RJ,et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographicmeasures of right ventricular structure and function in primarypulmonary hypertension. Primary Pulmonary Hypertension StudyGroup. Circulation, 1997.95:1479一1486 ) e1 ^3 o2 w. r" W
4 Y e& U, F0 x- h& d1 N! P" [ B Hoeper MM, Galie N, Simonneau G, et al. New treatmentsfor pulmonary arterial hypertension. Am J Respir Crit Care Med,2002.165:1209一1216 & y+ I' g$ f/ J+ p* ?/ _5 ?
" R3 Q& _5 w& B9 E2 h
Hoeper MM, Schwarze M, Ehlerding S, et al. Long-termtreatment of primary pulmonary hypertension with aerosolized ilo-prost, a prostacyclin analogue. N Engl J Med,2000.342:1866一1870
- C9 D& {( M* `( C$ j) x
3 @; W9 R! I4 ~+ M' N7 @% I, |* J# @ Horn EM, Barst RJ, Poon M. Epoprostenol for treatment ofpulmonary hypertension in patients with systemic lupus erythe-matosus. Chest,2000.118:1229一1230 $ U) F5 |" Q, a$ T5 _/ `% R
3 l1 H) @; |8 Y3 ^& S
Humbert M, Sanchez O, Fartoukh M, et al. Short-termand long-term epoprostenol (prostacyclin) therapy in pulmonaryhypertension secondary to connectivetissue diseases: results of apilot study. Eur Respir J,1999.13:1351一1356
& } }8 o: {9 p
* V1 B* P2 ^& i9 k. t7 T# S! g Klings ES, Hill NS, leong MH, et al. Systemic sclerosis-as-sociated pulmonary hypertension: short-and long-term effects ofepoprostenol (prostacyclin).Arthritis Rheum, 1999. 42: 2638-2645 5 K6 J4 p9 Q( P& q% U
3 t4 X" O$ \$ R6 ?( K Koh ET, Lee P, Gladman DD, et al. Pulmonary hyperten-sion in systemic sclerosis: an analysis of 17 patients. Br. JRheumatol,1996.35:989一993 * h d+ `4 B9 q% I! f& X
9 x8 T" h( c: y/ ^
Kunieda T. Diagnosis and treatment of pulmonary hyperten-sion associated with collagen diseases. Intern Med,2000. 39:280一282 2 `6 @8 K4 G, W \4 z7 W
Launay D, Hachulla E, Hatron PY, et al. Pulmonary hyper-tension screening in systemic scleroderma: a cohort study of 67patients. Rev Med Interne,2001.22:819一829 8 m/ J, a" R( o0 g5 R) E, b
3 C$ x$ ]# v* r7 I( w$ Z j
Li EK, Tam LS. Pulmonary hypertension in systemic lupuserythematosus: clinical association and survival in 18 patients. JRheumato1,1999.26:1923一1929
3 Y* P9 [; J: |$ R* D7 f
5 A( p! t+ R" l) r6 r$ p c% t, M McLaughlin VV, Genthner DE, Panella MM, et al, Reduc-tion in pulmonary vascular resistance with long-term epoprostenol(prostacyclin) therapy in primary pulmonary hypertension. NEngl J Med,1998. 338:273一277
: c9 D$ T m$ {+ ~6 m, R* q; {& u# s9 |: _, F
McLaughlin VV, Genthner DE, Panella MM, et al. Com-passionate use of continuous prostacyclin in the management ofsecondary pulmonary hypertension: a case series. Ann InternMed,1999.130:740一743
( `* s7 ~) O4 d$ H5 b8 n
, h3 @6 F9 a" e1 h1 B; m# V- x Murata I, Takenaka K, Yoshinoya S, et al. Clinical evalua-tion of pulmonary hypertension in systemic sclerosis and relateddisorders. A Doppler echocardiographic study of 135 Japanese pa-tients. Chest, 1997.111:36一43
" i3 R/ L7 D8 ?8 D/ Y B, Z G
2 f/ G4 L j- m4 V Nishimaki T, Aotsuka S, Kondo H, et al. Immunologicalanalysis of pulmonary hypertension in connective tissue diseases. JRheumato1,1999. 26:2357一2362 ) R2 |" A6 W! ~: C, B
3 ]! I& j0 a$ A* c8 \2 B* @5 h
Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension sec-ondary to lung fibrosis. Am J Respir Crit Care Med,1999. 160:600一607
% @8 q" ?; O2 R+ Q+ p% |# k9 u
) y7 }& h! l6 _ Ooiwa H, Miyazawa T, Yamanishi Y, et al. Successfultreatment of systemic lupus erythematosus and pulmonary hyper-tension with intravenous prostaglandin 12 followed by its oral ana-logue. Intern Med,2000.39:320一323 , j, N- x! L+ v5 N% e' V5 K _5 W" ?
- k; }( {1 g5 V& J2 E' ]
Pan TL, Thumboo J, Boey ML. Primary and secondary put-monary hypertension in systemic lupus erythematosus. Lupus,2000.9:338一342
) f* Z& R5 w7 }5 x! } P" w4 u: W0 I. i. Q% {: U# H* r( K- q6 \* s
Robbins IM, Gaine SP, Schilz R, et al. Epoprostenol fortreatment of pulmonary hypertension in patients with systemic lu-pus erythematosus. Chest,2000.117:14一18 b, D% A5 B6 ?7 v+ `5 n
/ x& F% M2 V+ U ] Rubin LJ, Badesch DB, Barst RJ,et al. Bosentan therapyfor pulmonary arterial hypertension. N Engl J Med, 2002. 346:896一903 4 B" V: r% P' s' C9 t
Sanchez O, Humbert M, Sitbon O, et al. Treatment of pul-monary hypertension secondary to connective tissue diseases.Thorax, 1999.54:273一277 1 @; h& p3 j! Y% m0 `1 z4 @
# b2 I+ ?* o! k8 |' I) K1 ] Sato N, Kyotani S, Sakamaki fi, et al. Pulmonary throm-boendarterectomy for chronic pulmonary thromboembolism inthree patients with systemic lupus erythematosus and antiphos-pholipid syndrome. Nihon Kokyuki Gakkai Zasshi, 2000. 38:958 一964 . L. f4 V* \3 C% g! O
( v7 {+ o' @0 N8 F" X. t Simonneau G, Barst RJ,Galie N, et al. Continuous subcuta-neous infusion of treprostinil, a prostacyclin analogue, in patientswith pulmonary arterial hypertension: a double-blind, random-ized, placebo-controlled trial. Am J Respir Crit Care Med,2002.165:800一804
) k' D: `1 z' q; F0 c5 y4 ^ Vizza CD, Sciomer S, Morelli S, et al. Long term treatmentof pulmonary arterial hypertension with beraprost, an oral prosta-cyclin analogue. Heart,2001.86:661一665
+ j' Y) d' H6 i- ^4 p+ c; i) o$ O& c
Wensel R, Opitz CF, Ewert R, et al. Effects of iloprost in-halation on exercise capacity and ventilatory efficiency in patientswith primary pulmonary hypertension. Circulation, 2000. 101:2388一2392 . D& v1 U0 c, f8 {1 _/ [
1 f. z0 o: e4 s0 X" r/ I& a0 V4 Y Winslow TM, Ossipov MA, Fazio GP, et al. Five-year fol-low-up study of the prevalence and progression of pulmonary by-pertension in systemic lupus erythematosus. Am Heart J, 1995.129:510一515 $ u5 \4 e0 ^: a, p
/ c9 O3 n4 g! x$ ?. r, I8 ^ Yamane K, Ihn H, Asano Y, et al. Clinical and laboratoryfeatures of scleroderma patients with pulmonary hypertension.Rheumatology(Oxford), 2000.39:1269一1271 |
|